-
公开(公告)号:US11117924B2
公开(公告)日:2021-09-14
申请号:US15742424
申请日:2016-07-06
IPC分类号: C07J9/00 , A61P23/00 , A61P25/20 , A61P3/00 , C07J17/00 , C07J31/00 , C07J7/00 , C07J13/00 , C07J41/00
摘要: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, and R3 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
-
公开(公告)号:US20210171567A1
公开(公告)日:2021-06-10
申请号:US16930047
申请日:2020-07-15
IPC分类号: C07J9/00
摘要: Compounds are provided according to Formula (III): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R5, and n are as defined herein, and at least one hydrogen is replaced with a deuterium. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
-
公开(公告)号:US20210061850A1
公开(公告)日:2021-03-04
申请号:US17097569
申请日:2020-11-13
发明人: Gabriel Martinez Botella , Boyd L. Harrison , Albert Jean Robichaud , Francesco G. Salituro , Richard Thomas Beresis
摘要: Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
-
公开(公告)号:US10774108B2
公开(公告)日:2020-09-15
申请号:US15531313
申请日:2015-11-27
发明人: Gabriel Martinez Botella , Boyd L. Harrison , Albert Jean Robichaud , Francesco G. Salituro , Richard Thomas Beresis
IPC分类号: C07J41/00 , C07J9/00 , C07J33/00 , C07J43/00 , C07J3/00 , C07J17/00 , C07J31/00 , A61K45/06 , A61K31/56
摘要: Described herein are neuroactive steroids of the Formula (II): or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
-
公开(公告)号:US10752653B2
公开(公告)日:2020-08-25
申请号:US16099122
申请日:2017-05-05
IPC分类号: C07J9/00
摘要: Compounds are provided according to Formula (III) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R5, and n are as defined herein, and at least one hydrogen is replaced with a deuterium. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
-
公开(公告)号:US10745436B2
公开(公告)日:2020-08-18
申请号:US16269779
申请日:2019-02-07
摘要: Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
-
公开(公告)号:US20200002371A1
公开(公告)日:2020-01-02
申请号:US16315250
申请日:2017-07-07
发明人: Francesco G. Salituro , Albert Jean Robichaud , Gabriel Martinez Botella , Boyd L. Harrison , Andrew Griffin , Daniel La
IPC分类号: C07J9/00
摘要: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, and R6, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
-
公开(公告)号:US20190359646A1
公开(公告)日:2019-11-28
申请号:US16099122
申请日:2017-05-05
IPC分类号: C07J9/00
摘要: Compounds are provided according to Formula (III) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R5, and n are as defined herein, and at least one hydrogen is replaced with a deuterium. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
-
公开(公告)号:US10435431B2
公开(公告)日:2019-10-08
申请号:US15681983
申请日:2017-08-21
发明人: Ravindra B. Upasani , Benny C. Askew , Boyd L. Harrison , Francesco G. Salituro , Albert J. Robichaud
摘要: Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I) and (III): where R1, R2, R3, R3′, R4, R6a, R6a, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, insomnia, anxiety, depression, traumatic brain injury (TBI), stress, and epilepsy.
-
公开(公告)号:US20190233465A1
公开(公告)日:2019-08-01
申请号:US16316851
申请日:2017-07-11
发明人: Albert Jean Robichaud , Gabriel Martinez Botella , Boyd L. Harrison , Francesco G. Salituro , Andrew Griffin , Maria Jesus Blanco-Pillado
CPC分类号: C07J43/003 , A61P25/00 , C07J1/0029 , C07J7/002 , C07J7/003 , C07J7/006 , C07J41/005 , C07J41/0094
摘要: Described herein are neuroactive steroids of Formula (I), Formula (V), or Formula (IX) or a pharmaceutically acceptable salt thereof; wherein each instance of R2, R3, R4, R5, R6, R7, R11a, R11b, R12, R16, R17, R19, and are as herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.
-
-
-
-
-
-
-
-
-